U.S. Stock News

Shelf registration puts funding options on the table National Fuel Gas (NFG) has filed an omnibus shelf registration covering debt, common and preferred stock, depositary shares, stock purchase contracts and units. This filing refreshes the company’s ability to raise capital through multiple security types. See our latest analysis for National Fuel Gas. At a share price of US$83.37, National Fuel Gas has seen a 1-day share price return of 1.89% and a 30-day share price return of 3.00%. The...

Tango Therapeutics, Inc. recently reported a wider net loss of US$55.34 million for the second quarter of 2026, filed a US$400 million at-the-market follow-on equity offering, and made several leadership changes including appointing a new Chairman and a future Chief Commercialization Officer. These moves point to a company aligning its capital-raising plans with the build-out of commercialization expertise as it prepares vopimetostat for later-stage development. Next, we will examine how the...

What Viridian Therapeutics’ Latest Earnings Mean For Investors Viridian Therapeutics (VRDN) reported its second quarter and six month results to June 30, 2026, giving investors fresh detail on revenue and losses that appear to be driving recent stock interest. Quarterly revenue was US$0.284 million compared with US$0.075 million a year earlier. Net loss for the period was US$127.12 million, with basic loss per share from continuing operations at US$1.05 compared with US$1 in the prior year...

In August 2026, MDU Resources Group’s board raised its quarterly dividend to US$0.145 per share, updated its long‑term dividend payout ratio target to 55%–65% of earnings, and set an October 1, 2026 payment date for shareholders of record on September 10, 2026. This combination of a higher cash payout and a lower target payout range highlights management’s focus on balancing income returns with earnings retention for future investment. Next, we’ll examine how the dividend increase and...

Recently, Prosperity Bancshares was highlighted for offering a 3.2% dividend yield, above both its banking peers and the S&P 500, with five years of consistent dividend increases supported by a payout ratio of about 40% of earnings. An interesting angle for investors is how this combination of above-average yield, measured dividend growth and a seemingly sustainable payout level is refocusing attention on Prosperity Bancshares’ income profile. We’ll now examine how Prosperity Bancshares’...

Event context for CONMED and recent performance snapshot Recent commentary on CONMED (CNMD) highlights adoption of its AirSeal, Buffalo Filter, and BioBrace platforms alongside tariff and product specific growth risks. Investors are weighing this product mix against the stock’s recent share price moves. See our latest analysis for CONMED. At a share price of US$49.26, CONMED has seen its 30 day share price return of 14.03% and 90 day share price return of 33.10% contrast with a 1 year total...

Why BBB Foods Stock Is Back In Focus After Earnings And Capital Plans BBB Foods (TBBB) is drawing attention after reporting second quarter and half year results that paired higher revenue with wider net losses, followed closely by a large shelf registration for potential share issuance. See our latest analysis for BBB Foods. The recent earnings update and US$1.53b shelf registration appear to have sharpened focus on BBB Foods, with the share price at US$48.06 after a 7 day share price return...

Long term Treasury yields near multi decade highs are reshaping where credit risk feels most exposed. AI and tech stocks tied to heavy spending are being repriced as debt, not just growth stories, which is pulling attention toward listed private credit and alternative lenders. This article walks through three stocks from that universe that appear well positioned relative to these shocks and explains how their exposure to the news could matter for your portfolio. The three listed private...

DXP Enterprises reported past second-quarter 2026 results showing sales of US$576.46 million and net income of US$28.71 million, with both basic and diluted earnings per share from continuing operations higher than a year earlier. Over the first half of 2026, DXP’s higher sales and earnings, alongside prior commentary about strong long-term revenue and earnings-per-share expansion, highlight how its growth initiatives are translating into improved profitability. With this earnings strength...

In August 2026, Oruka Therapeutics, Inc. reported second-quarter and six-month results showing net losses of US$41.21 million and US$73.03 million, respectively, with basic loss per share from continuing operations rising to US$0.55 for the quarter and US$1.04 for the half year compared with the prior period. The results highlight that Oruka’s losses and loss per share have increased compared with a year earlier, sharpening investor focus on how the company is funding and pacing its...

AtaiBeckley (ATAI) drew fresh attention after releasing second quarter 2026 results, reporting revenue of US$1.7 million and a net loss of US$32.52 million, while loss per share from continuing operations improved year over year. See our latest analysis for AtaiBeckley. AtaiBeckley’s recent earnings release comes after a sharp shift in sentiment, with a 90 day share price return of 78.24% and a 3 year total shareholder return above 300%, although the 5 year total shareholder return remains...

In August 2026, Enovis Corporation reported second-quarter 2026 results showing sales of US$582.78 million and a reduced net loss of US$1.19 million, while six-month sales reached US$1.17 billion with a smaller net loss of US$9.95 million compared with the prior year. At the same time, Enovis reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic revenue growth, underscoring management’s confidence in the business trajectory despite losses. We will...

Entergy stock has delivered very strong returns over the past three years, yet the current valuation signals are cautious, with the Dividend Discount Model (DDM) implying the shares trade at a premium to its estimated intrinsic value while the broader checks do not point to a clear bargain. Entergy has returned 151.5% over the past three years, which puts recent gains under the spotlight when judging whether the current price still offers an attractive entry point. Expectations for steady...

Erasca (ERAS) is back in focus after reporting second quarter 2026 results that showed a wider net loss, alongside the appointment of veteran oncology leader Charles S. Fuchs as president of research and development. See our latest analysis for Erasca. Erasca’s recent earnings release, shelf registration filing of up to US$112.344 million and the ongoing securities class action have all landed while the stock trades at US$18.10, with a 90 day share price return of 55.97% and a year to date...

Schrödinger (SDGR) is back in focus after reporting second quarter 2026 results that moved from a loss to a profit, along with a new agreement to deploy its Bunsen AI co-scientist with Bristol Myers Squibb. See our latest analysis for Schrödinger. At a share price of $17.67, Schrödinger has seen a 43.4% 90 day share price return and a 15.3% 30 day share price return, although the 1 year total shareholder return is down 8.9%. This suggests recent momentum has picked up following the move to...

Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial.

Optimi Health has added financial flexibility to its growth strategy as it advances its MDMA and psilocybin business.

ADMA Biologics (ADMA) stock is back in focus after the company reported second quarter 2026 results, highlighted by US$124.4 million in sales and US$37.82 million in net income, along with reaffirmed full year revenue guidance. See our latest analysis for ADMA Biologics. At a share price of US$9.54, ADMA Biologics has seen a 1 month share price return of 9.53% and a 3 month share price return of 11.45%. However, the year to date share price return is down 46.64%, while the 5 year total...

Graham stock moves after contract wins, earnings update and guidance reaffirmation Graham (GHM) stock has been reacting to a cluster of recent company updates, including more than US$43 million in new defense contracts, first quarter fiscal 2027 results, and reaffirmed full year sales guidance. See our latest analysis for Graham. Graham’s recent contract awards, earnings update and reaffirmed guidance come after a period of strong share price momentum, with a 90 day share price return of...

In August 2026, Ligand Pharmaceuticals reported past second-quarter 2026 results showing revenue of US$63.69 million and net income of US$48.51 million, with basic earnings per share from continuing operations of US$2.42, alongside stronger first-half results than the prior year. Importantly for longer-term watchers, Ligand also reaffirmed its 2026 guidance for total revenue of US$270 million to US$310 million and GAAP net income of US$107 million to US$118 million, underscoring...

Texas Capital Bancshares (TCBI) is in focus after Texas Capital Bank Private Wealth Advisors and Texas Capital Funds Trust moved to shift two Texas focused ETFs from the New York Stock Exchange to the new Texas Stock Exchange. See our latest analysis for Texas Capital Bancshares. At a share price of $99.83, Texas Capital Bancshares has seen some recent pressure, with the 1 month share price return down 4.99%. However, the year to date share price return of 8.87% and 1 year total shareholder...

Aveanna Healthcare Holdings Inc. recently reported past second-quarter 2026 results showing sales of US$670.48 million and net income of US$40.29 million, alongside modest impairment charges of US$145,000. Management also raised full-year revenue guidance to more than US$2.68 billion, signaling increased confidence in the company’s operating performance and demand backdrop. We’ll now examine how Aveanna’s raised full-year revenue guidance reshapes its existing investment narrative for...

AI is putting a fresh spotlight on who really profits from personal data, with proposals for $15,000 annual payments to families and talk of a $300b data market and trillion dollar AI IPOs. That debate could reshape how digital payments and benefits infrastructure businesses earn, tax and regulate revenue streams. This article looks at three US stocks exposed to that story and why their future cash flows may matter to your portfolio. The stocks highlighted below are just a sample, and the...

Privia Health Group, Inc. recently reported second-quarter 2026 results showing higher sales of US$632.63 million and improved profitability, and raised its full-year 2026 GAAP revenue outlook to the high end of its prior US$2.35 billion to US$2.45 billion range. The company also appointed experienced healthcare executive and physician Opella Ernest, M.D. to its Board and Compliance Committee, adding deep payer, clinical, and regulatory expertise that could be important as Privia scales its...